Updates are available Correction dated 2025-03-11
Click to view Correction: https://doi.org/10.1007/s13679-025-00616-0
-
Authors
Heymsfield, Steven B. https://orcid.org/0000-0003-1127-9425
Clément, Karine https://orcid.org/0000-0002-2489-3355
Dubern, Beatrice https://orcid.org/0000-0002-0065-5344
Goldstone, Anthony P. https://orcid.org/0000-0001-8179-7071
Haqq, Andrea M. https://orcid.org/0000-0002-6256-4982
Kühnen, Peter https://orcid.org/0000-0003-0211-176X
Richards, Jesse https://orcid.org/0009-0004-7985-8882
Roth, Christian L. https://orcid.org/0000-0003-3037-4057
Akker, Erica L. T. van den https://orcid.org/0000-0001-5352-9328
Wabitsch, Martin https://orcid.org/0000-0001-6795-8430
Yanovski, Jack A. https://orcid.org/0000-0001-8542-1637
-
Funding
Funding for this research was provided by:
Rhythm Pharmaceuticals, Inc.
- License Information
-
More Information
Article History
Accepted: 11 December 2024
First Online: 25 January 2025
Change Date: 11 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13679-025-00616-0
Declarations
:
: All roundtable participants received honorarium and travel reimbursements from Rhythm Pharmaceuticals, Inc. Authors were not paid for their participation in this manuscript. SBH is a medical advisory board member for Tanita Corporation, Amgen, Novo Nordisk, Versanis Bio, and Medifast and has served as an Amazon Scholar. KC is a primary investigator for Rhythm Pharmaceuticals, Inc. and her research group has received research support from Rhythm Pharmaceuticals, Inc. BD is a consultant for Novo Nordisk and primary investigator for Rhythm Pharmaceuticals, Inc. APG has been a consultant for Evidera, Helsinn Healthcare, Idera Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Soleno Therapeutics, Tonix Pharmaceuticals, and Veda Ventures; has been an advisory board member for Millendo Therapeutics and Radius Health; has been a member of the Data Safety Monitoring Committee for Novo Nordisk; has received speaker honoraria from Novo Nordisk and Rhythm Pharmaceuticals, Inc.; and has been a Principal Investigator for clinical trials sponsored by Millendo Therapeutics, Rhythm Pharmaceuticals, Inc., and Soleno Therapeutics. AMH has received grants from the Weston Family Microbiome Initiative and Canadian Institutes of Health Research and is an advisory board member for Rhythm Pharmaceuticals, Inc., the 2023 Novo Nordisk Pediatric Expert Obesity National, and Foundation for Prader-Willi Research USA. She is PI for clinical trials with Rhythm Pharmaceuticals, Inc., Acadia Pharmaceuticals, NovoNordisk, and Eli Lilly. PK has participated on a safety board for and their institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. JR is on speaker bureaus for Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals, Inc. and is an independent consultant for Palatin Technologies. CLR’s institution has received research support from Rhythm Pharmaceuticals, Inc. EvdA’s institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. MW has received consulting fees and payment for educational events/lectures from Rhythm Pharmaceuticals, Inc. and their institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. JAY reports grant support from Soleno Therapeutics and Rhythm Pharmaceuticals, Inc. for obesity-related projects as well as material support for research from Hikma Pharmaceuticals plc and Versanis Bio.
